	US 12,291,557 B2
	Chimeric TIM4 receptors and uses thereof
Daniel Mark Corey, Menlo Park, CA (US)
Assigned to CERO THERAPEUTICS HOLDINGS, INC., South San Francisco, CA (US)
Appl. No. 17/040,317
Filed by CERO THERAPEUTICS HOLDINGS, INC., South San Francisco, CA (US)
PCT Filed Mar. 27, 2019, PCT No. PCT/US2019/024435 § 371(c)(1), (2) Date Sep. 22, 2020, PCT Pub. No. WO2019/191334, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/649,491, filed on Mar. 28, 2018.
Prior Publication US 2021/0087251 A1, Mar. 25, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/705 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/4257 (2025.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C12N 5/0636 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)]

11 Claims

1. A chimeric Tim4 receptor comprising a single chain chimeric protein, the single chain chimeric protein comprising:

a receptor binding domain comprising a Tim4 binding domain;

an intracellular signaling domain comprising a CD28 costimulatory signaling domain and a CD3ζ signaling domain; and

a transmembrane domain positioned between and connecting the receptor binding domain and the intracellular signaling domain.